After nearly six months of shortage, Rivotril (clonazepam) in drop form of 2.5 mg is making its way back to the shelves of pharmacies in Brazil. This information has been confirmed by major pharmacy chains across the country and Biopas Brasil Produtos Farmacêuticos, which is responsible for marketing the medication. They have resumed distribution following updates to their manufacturing plant in Italy.

However, the sublingual version of Rivotril at 0.25 mg, which has also been unavailable, has not yet returned to the market. According to Biopas, this product is still in the final stages of its transition to a new manufacturing facility in Spain, with an expected return to the market slated for the first half of 2026. The interruption in supply occurred during the transfer of production to these new industrial units in Europe, a situation previously reported by Folha in September 2025.

The ongoing shortage of the sublingual version poses a challenge for patients who rely on this medication, highlighting the complexities involved in pharmaceutical manufacturing and distribution. As Brazil navigates these supply chain issues, the healthcare system may need to consider alternative solutions to ensure patients have access to their required medications during this transition period.